Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of multiple myeloma, lymphoma, and leukemia

Abstract

A cannabis -based flavonoid pharmaceutical composition for treatment of multiple myeloma, lymphoma, and leukemia, the composition including any one or more selected from among the group of Cannflavin A, Cannflavin B, Cannflavin C, FBL-03G (Caflanone), Chiysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases

We claim: 
     
         1 . A  cannabis -based flavonoid pharmaceutical composition for the prevention and treatment of multiple myeloma, lymphoma, and leukemia having a general flavone backbone (2-phenyl-1,4-benzopyrone) chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein R1, R3, R5, R6, R7 and R10 may be none, any one or more substituents selected from the group consisting of a hydrogen molecule (H), a hydroxide molecule (OH), a methyl group comprising one carbon atom bonded to three hydrogen atoms (CH3), an alkoxy group (O—CH3), a carboxyl group (COOH), chlorine (Cl), Bromine (Br), Fluorine (F), Glutamic acid (Glu), and any salts or derivatives of the foregoing, R2, R4, R8 and R9 may be any one or more substituents selected from said group, and A and B may be linked by either a single or double bond. 
       
     
     
         2 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         4 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         6 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         8 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         10 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         11 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         12 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 1 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         13 . A  cannabis -based flavonoid pharmaceutical composition for the prevention and treatment of multiple myeloma, lymphoma, and leukemia having a general flavone backbone (2-phenyl-1,4-benzopyrone) chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         R2 may be one or more substituents selected from the group consisting of a hydrogen molecule (H), a hydroxide molecule (OH), or an oxygen molecule (0); 
         R3 may be none, or one or more hydrogen molecules (H), 
         R4 may be none, or any one or more substituents selected from the group consisting of a hydroxide molecule (OH) or a nitrogen dioxide molecule (NO2); 
         R5 and R8 may be none, or a hydroxide molecule (OH); 
         R7 may be none, or the amine NH2; 
         R9 may be none, or any one or more substituents selected from the group consisting of a hydroxide molecule (OH) or an oxygen molecule (0); 
         and A and B may be be linked by either a single or double bond. 
       
     
     
         14 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 13 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         15 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 13 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         16 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 13 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         17 . The  cannabis -based flavonoid pharmaceutical composition according to  claim 13 , having a specific chemical structure as shown below, or any pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         18 . A method of treating multiple myeloma, lymphoma, and leukemia, the method comprising administering the general composition of  claim 1 .